We are truly sorry that information is missing here.
We are currently working on this piece of information and it will be available as soon as possible.
Please come back soon!
Kineret® is a medicine that is used to reduce the pain and swelling associated with moderate
to severe active rheumatoid arthritis. Kineret® is a man-made protein that is similar to a naturally
occurring protein called interleukin-1 receptor antagonist (IL-1ra) found in the body. Kineret® is
for use by patients eighteen years of age or older and for patients who have not responded to treatment
with other agents called disease-modifying antirheumatic drugs or DMARDS. Kineret® can be used by itself
or in combination with DMARDS. Kineret® should not be used with medicines called Tumor Necrosis Factor
(TNF) blocking agents such as ENBREL® (etanercept), Humira™ (adalimumab), or Remicade® (infliximab).
In clinical trials there was a risk of serious infections (2% in Kineret® patients vs. less
than 1% in placebo patients). Kineret® should be discontinued if you develop an infection,
however most often you can continue taking Kineret® after your infection resolves.
You should not use Kineret® if you are taking TNF-blocking agents, such as etanercept,
adalimumab, and infliximab, unless your doctor has told you to do so. If you use Kineret®
with etanercept, adalimumab, or infliximab you may increase your risk of getting a serious infection.
Kineret® should not be used if you know you are hypersensitive to E coli-derived proteins,
Kineret®, or any ingredient of the product. The most common side effect in clinical trials was a
reaction at the site of injection, which was usually mild and characterized by redness, swelling, and pain.
